Tag: medicine

Hua Medicine (the “Company”, Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). Dorzagliatin is the first glucokinase activator (GKA) to submit a NDA for the treatment of diabetes, and has the potential to become the first first-in-class drug to be launched in China. Relying on Hua Medicine’s original scientific concept of “repair the sensor, restore homeostasis, and treat the underlying cause of diabetes,” the Company has always focused on addressing unmet medical needs since its establishment. The ... Read more